Pratik Bhojnagarwala

2.5k citations

23 papers · 1.3k indexed · 1 hit paper · h-index 12

Immunology top 2%
- Immunotherapy and Immune Responses 13
- Immune Cell Function and Interaction 5
- Immune cells in cancer 5
Oncology top 5%
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 6
Cancer Research
Biotechnology
- Cancer Research and Treatments 3
Pulmonary and Respiratory Medicine
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 5
Molecular Biology
- RNA Interference and Gene Delivery 2

Co-authors: Sunil Singhal Evgeniy Eruslanov Steven Μ. Albelda Wayne W. Hancock Jon G. Quatromoni Leslie A. Litzky Charuhas Deshpande José R. Conejo-García
Cited by: Immunology Oncology Cancer Research
Journals: Journal of Clinical Investigation (1 paper)PLoS ONE (1 paper)Cancer Cell (1 paper)
Partner nations: United States

In The Last Decade

Pratik Bhojnagarwala

22 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Pratik Bhojnagarwala

Since Specialization

Citations

This map shows the geographic impact of Pratik Bhojnagarwala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pratik Bhojnagarwala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pratik Bhojnagarwala more than expected).

Fields of papers citing papers by Pratik Bhojnagarwala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pratik Bhojnagarwala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pratik Bhojnagarwala. The network helps show where Pratik Bhojnagarwala may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Pratik Bhojnagarwala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pratik Bhojnagarwala Line = papers co-authored together Pratik Bhojnagarwala links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets Molecular Therapy ·Pratik Bhojnagarwala,Joshua Jose,Shushu Zhao,David B. Weiner	2025	1
2	Structural engineering of stabilized, expanded epitope nanoparticle vaccines for HPV Frontiers in Immunology ·Michaela Helble,Xizhou Zhu,Pratik Bhojnagarwala,Kevin Liaw,Yun Gao,Amber Kim,Kelly Bayruns,Madison E. McCanna,Joyce Park,Kylie M. Konrath,Samuel E. Garfinkle,Taylor V. Brysgel,David B. Weiner,Daniel W. Kulp	2025	0
3	Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma Journal for ImmunoTherapy of Cancer ·Ryan P. O’Connell,Kevin Liaw,Nils Wellhausen,Christopher A Chuckran,Pratik Bhojnagarwala,Devivasha Bordoloi,Daniel H. Park,Nicholas Shupin,Daniel W. Kulp,Carl H. June,David B. Weiner	2024	6
4	Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells Journal for ImmunoTherapy of Cancer ·Daniel H. Park,Pratik Bhojnagarwala,Kevin Liaw,Devivasha Bordoloi,Nicholas J. Tursi,Shushu Zhao,Zev A. Binder,Donald M. O’Rourke,David B. Weiner	2024	4
5	Abstract PR-006: A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer Cancer Research ·Devivasha Bordoloi,Abhijeet J. Kulkarni,Opeyemi S. Adeniji,Pratik Bhojnagarwala,Shushu Zhao,Candice Ionescu,Mohamed bdel-Mohsen,David B. Weiner	2024	1
6	Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape Molecular Therapy — Oncolytics ·Daniel H. Park,Kevin Liaw,Pratik Bhojnagarwala,Xizhou Zhu,Jihae Choi,Ali Ali,Devivasha Bordoloi,E. Gary,Ryan P. O’Connell,Abhijeet J. Kulkarni,Diana Guimet,Trevor R.F. Smith,Alfredo Perales‐Puchalt,Ami Patel,David B. Weiner	2023	11
7	A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy JCI Insight ·Devivasha Bordoloi,Pratik Bhojnagarwala,Alfredo Perales‐Puchalt,Abhijeet J. Kulkarni,Xizhou Zhu,Kevin Liaw,Ryan P. O’Connell,Daniel H. Park,Daniel W. Kulp,Rugang Zhang,David B. Weiner	2022	14
8	1174 Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy Regular and Young Investigator Award Abstracts ·Pratik Bhojnagarwala,Alfredo Perales‐Puchalt,E. Gary,Niranjan Y. Sardesai,David B. Weiner	2022	1
9	In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme Molecular Therapy — Oncolytics ·Pratik Bhojnagarwala,Ryan P. O’Connell,Daniel Park,Kevin Liaw,Ali Ali,Devivasha Bordoloi,Joel Cassel,Nicholas J. Tursi,E. Gary,David B. Weiner	2022	12
10	DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas Molecular Therapy — Oncolytics ·Xizhou Zhu,Alfredo Perales‐Puchalt,Krzysztof Wojtak,Ziyang Xu,Kun Yun,Pratik Bhojnagarwala,Devivasha Bordoloi,Daniel H. Park,Kevin Liaw,Mamadou A. Bah,Paul M. Lieberman,E. Gary,Ami Patel,David B. Weiner	2021	5
11	A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation Molecular Therapy — Oncolytics ·Pratik Bhojnagarwala,Alfredo Perales‐Puchalt,Neil Cooch,Niranjan Y. Sardesai,David B. Weiner	2021	13
12	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer Science Translational Medicine ·Sunil Singhal,Jason Stadanlick,Michael J. Annunziata,Abhishek Rao,Pratik Bhojnagarwala,Shaun O’Brien,Edmund K. Moon,Edward Cantu,Gwenn Danet-Desnoyers,Hyun-Jeong Ra,Leslie A. Litzky,Tatiana Akimova,Ulf H. Beier,Wayne W. Hancock,Steven Μ. Albelda,Evgeniy Eruslanov	2019	183
13	Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms Scientific Reports ·Dmitri Negorev,Ulf H. Beier,Tianyi Zhang,Jon G. Quatromoni,Pratik Bhojnagarwala,Steven Μ. Albelda,Sunil Singhal,Evgeniy Eruslanov,Falk W. Lohoff,Matthew H. Levine,Joshua M. Diamond,Jason D. Christie,Wayne W. Hancock,Tatiana Akimova	2018	28
14	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer Cancer Cell ·Sunil Singhal,Pratik Bhojnagarwala,Shaun O’Brien,Edmund K. Moon,Alfred L. Garfall,Abhishek S. Rao,Jon G. Quatromoni,Tom L. Stephen,Leslie A. Litzky,Charuhas Deshpande,Michael D. Feldman,Wayne W. Hancock,José R. Conejo-García,Steven Μ. Albelda,Evgeniy Eruslanov	2016	334
15	Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma Immunology Letters ·Gregory T. Kennedy,Brendan F. Judy,Pratik Bhojnagarwala,Edmund K. Moon,Zvi G. Fridlender,Steven Μ. Albelda,Sunil Singhal	2015	3
16	Abstract 1291: Tumor-infiltrating FOXP3+ T-regulatory (Treg) cells in early-stage human lung cancer exhibit enhanced suppressive function when compared to blood or lymph node (LN) Treg cells Cancer Research ·Tatiana Akimova,Evgeniy Eruslanov,Pratik Bhojnagarwala,Jon G. Quatromoni,Jacqueline Morgen,Sunil Singhal,Steven Μ. Albelda,Wayne W. Hancock	2015	1
17	Intraoperative Near-Infrared Imaging Can Distinguish Cancer from Normal Tissue but Not Inflammation PLoS ONE ·David E. Holt,Olugbenga T. Okusanya,Ryan Judy,Ollin Venegas,Jack Jiang,Elizabeth DeJesus,Evgeniy Eruslanov,Jon G. Quatromoni,Pratik Bhojnagarwala,Charuhas Deshpande,Steven Μ. Albelda,Shuming Nie,Sunil Singhal	2014	111
18	Adenoviral-Based Immunotherapy Provides Local Disease Control in an Orthotopic Murine Model of Esophageal Cancer Journal of Immunotherapy ·Jon G. Quatromoni,Jarrod D. Predina,Pratik Bhojnagarwala,Ryan Judy,Jack Jiang,Elizabeth M. De Jesus,Veena Kapoor,Guanjun Cheng,Olugbenga T. Okusanya,Evgeniy Eruslanov,Sunil Singhal	2014	8
19	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancerbreakdown → Journal of Clinical Investigation ·Evgeniy Eruslanov,Pratik Bhojnagarwala,Jon G. Quatromoni,Tom L. Stephen,Anjana Ranganathan,Charuhas Deshpande,Tatiana Akimova,Anil Vachani,Leslie A. Litzky,Wayne W. Hancock,José R. Conejo-García,Michael D. Feldman,Steven Μ. Albelda,Sunil Singhal	2014	495
20	The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T Cells BMC Immunology ·Jon G. Quatromoni,Eiji Suzuki,Olugbenga T. Okusanya,Brendan F. Judy,Pratik Bhojnagarwala,Ollin Venegas,Evgeniy Eruslanov,Jarrod D. Predina,Steven Μ. Albelda,Sunil Singhal	2013	11

About Pratik Bhojnagarwala

Pratik Bhojnagarwala is a scholar working on Immunology, Oncology and Biotechnology, having authored 23 papers that have together received 1.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (13 papers), Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (5 papers), Immune cells in cancer (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Cancer Research and Treatments (3 papers) and RNA Interference and Gene Delivery (2 papers). The work is most often cited by research in Immunology (955 citations), Oncology (587 citations) and Cancer Research (96 citations). Pratik Bhojnagarwala has collaborated with scholars based in United States. Frequent co-authors include Sunil Singhal, Evgeniy Eruslanov, Steven Μ. Albelda, Wayne W. Hancock, Jon G. Quatromoni, Leslie A. Litzky, Charuhas Deshpande, José R. Conejo-García, Tom L. Stephen and Michael D. Feldman. Their work appears in journals such as Journal of Clinical Investigation, PLoS ONE and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact